Cedars-Sinai Discovery May Aid Doctors in Diagnosing At-risk Patients Before Symptoms Appear
A team led by a Cedars-Sinai physician-scientist has discovered a biomarker—a protein found in the blood—for the most common type of heart failure, a new study published today in JAMA Cardiology shows.
Heart failure with preserved ejection fraction (HFpEF) affects more than 6.5 million Americans each year. And now, thanks to the discovery of the first-ever biomarker for HFpEF, a simple blood test can reveal whether a patient’s heart is not making enough of an important protein. If the protein levels are decreased, the biomarker signal increases and physicians will be able to diagnose heart failure sooner, prescribe corrective medicines and prevent further disease progression.
“By the time heart failure symptoms develop, the critical window for corrective therapy has typically closed,” said Robin Shaw, MD, PhD, the Wasserman Endowed Chair in Cardiology and professor of Medicine at the Smidt Heart Institute at Cedars-Sinai and principal investigator on the study. “Our discovery allows us to not only diagnose the disease sooner, but also to treat patients before that critical period of early intervention for lifesaving care has closed.”
Heart failure with preserved ejection fraction is a condition where the heart can contract, but has problems relaxing—limiting the heart’s ability to fill with blood between each beat—and therefore lowers the amount of blood moving forward with each contraction. Prior to the discovery of the biomarker, clinicians had to wait for patients to have symptoms to make a diagnosis of HFpEF and had to use an echocardiogram that measured how well the heart relaxed. There was no method to gauge the health of the heart muscle before symptoms developed or determine the severity of disease once symptoms were present.
The biomarker—named cBIN1 Score, or CS for short—allows doctors to measure muscle deterioration and measure a protein that regulates the heart’s ability to both contract and relax. As the protein decreases, CS increases, serving as an indication of onset heart failure. The CS biomarker can be measured using a simple blood draw.
This discovery will allow the most at-risk patients—including older patients and patients with high blood pressure, diabetes or dyslipidemia—to be checked during an annual exam from their primary care physician. This pivotal research has the potential to impact millions of people and serve as a critical tool for preventive heart care.
Eduardo Marbán, MD, PhD, director, Smidt Heart Institute
The CS biomarker is designed to be used in an outpatient clinic setting. For patients with known HFpEF, doctors can draw a CS level and use it to both guide current care, including medication adjustments, and predict the chances of a patient being admitted to the hospital in the next 12 months.
“More broadly, this discovery will allow the most at-risk patients—including older patients and patients with high blood pressure, diabetes or dyslipidemia—to be checked during an annual exam from their primary care physician,” said Eduardo Marbán, MD, PhD, director of the Smidt Heart Institute. “This pivotal research has the potential to impact millions of people and serve as a critical tool for preventive heart care.”
Symptoms of heart failure typically appear as fatigue, fluid weight gain, leg swelling and shortness of breath. Heart failure with preserved ejection fraction is typically diagnosed in elderly people or those living with high blood pressure, diabetes, elevated cholesterol, hypertension, obesity, obstructive sleep apnea, anemia, iron deficiency or diabetes. Its prevalence is projected to rise drastically over the coming decades. Previous studies have shown that women represent the majority of patients diagnosed with the disease.
As next steps, Cedars-Sinai researchers plan on identifying specialty populations in which the CS biomarker could be useful, including sex-based differences, those who have undergone a heart transplant or valve replacement, as well as individuals with no known heart disease or risk factors.
The Latest on: Heart failure
via Google News
The Latest on: Heart failure
- Framingham Heart Study Will Examine Aging with New $38M Funding on April 17, 2019 at 9:04 am
The country’s oldest heart disease study, run by Boston University and the National Heart, Lung, and Blood Institute (NHLBI), will research how aging affects the heart and other organs, from the brain ... […]
- Quantum Genomics Receives First Regulatory and Ethics Approvals to Initiate Phase IIb QUORUM Study of Firibastat in Heart Failure on April 17, 2019 at 9:00 am
Quantum Genomics (Euronext Growth: ALQGC, OTCQX: QNNTF), a biopharmaceutical company specializing in the development of a new drug class that directly targets the brain to treat resistant hypertension ... […]
- Stress Tied to Heart Disease, Especially in People Under 50 on April 17, 2019 at 8:48 am
Stress may increase the risk for heart disease, especially in younger people. Researchers writing in BMJ used Swedish data on 136,637 people diagnosed with stress-related disorders, including ... […]
- Diabetes drug Metformin may fight heart disease, study says on April 17, 2019 at 6:41 am
April 17 (UPI) --A drug commonly used to treat diabetes may also fight heart disease, a new study says. Metformin could reverse left ventricular hypertrophy, thickening of the heart muscle, which can ... […]
- Ischemic heart disease driver of cardiovascular hospitalizations after early-stage breast cancer on April 17, 2019 at 5:09 am
2019;doi:10.1093/jnci/djy218. Women with early-stage breast cancer had a significantly greater risk for cardiovascular disease hospitalizations than women without cancer, with ischemic heart disease ... […]
- Portneuf Medical Center Educates on Heart Disease on April 16, 2019 at 9:57 pm
There aren't many singular topics that could attract around 100 people to a class at a hospital. But, not every topic can call itself the most common killer in America. "Heart disease is something ... […]
- Diabetic drug shown to reduce the risk of heart disease in non-diabetic patients on April 16, 2019 at 5:06 pm
The commonly used diabetes drug metformin could reverse the harmful thickening of heart muscle that leads to cardiovascular disease, according to a study at the University of Dundee. Scientists ... […]
- The FDA’s New Sugar Label Could Seriously Reduce Heart Disease and Diabetes—And Boost Longevity on April 16, 2019 at 12:43 pm
Cardiovascular disease and diabetes are two leading causes of death in the US, responsible for over 715 thousand deaths in 2016 alone, yet both are preventable and reversible. And one of the major ... […]
- What Are My Medication Options for Systolic Heart Failure? Talk to Your Doctor on April 16, 2019 at 12:15 pm
Systolic heart failure is a condition in which the heart doesn’t pump normally. If your left ventricle doesn’t contract well enough, you may have systolic heart failure. Symptoms of systolic heart ... […]
via Bing News